TGX-1214 combination treatment for advanced pancreatic cancer
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
A new chemotherapy called TGX-1214 is being combined with immune checkpoint drugs to help people with advanced pancreatic cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11260149 on NIH RePORTER |
What this research studies
You would be hearing about a treatment that pairs a next-generation chemotherapy (TGX-1214 formulated as a nanoemulsion) with an immune checkpoint blocker to better attack stubborn pancreatic tumors. The team has seen strong tumor shrinkage and more CD8+ immune cells in mouse models, including genetically engineered models that mimic human pancreatic cancer. Researchers will build on those lab and animal results to refine the combo approach and prepare it for possible human testing. The work is led by investigators at UC Davis in partnership with industry and other universities.
Who could benefit from this research
Good fit: Future clinical testing would likely target people with advanced or treatment-refractory pancreatic ductal adenocarcinoma who have limited standard options.
Not a fit: People with early-stage pancreatic cancer, other cancer types, or those who cannot receive chemotherapy or immune therapy would likely not benefit from this specific approach.
Why it matters
Potential benefit: If successful, this approach could shrink tumors more effectively and boost immune attack, potentially improving outcomes for people with advanced pancreatic cancer.
How similar studies have performed: While immune checkpoint drugs alone have shown limited benefit in pancreatic cancer clinically, preclinical combinations of novel chemotherapies with PD-L1 blockade (including TGX-1214 in mice) have produced strong tumor responses.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Mackenzie, Gerardo Guillermo — University of California at Davis
- Study coordinator: Mackenzie, Gerardo Guillermo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.